Direct primary care provides medical treatment the old-fashioned way
Yet, health care is simply an economic activity, albeit where the activity between a provider and a patient is the most personal interchange an individual will ever have. However, because of the complexity, the vast majority of patients in the U.S. don't completely control their medical finances and, in many cases, their medical decisions.
Almost 90 percent of Americans have their health care provided through their employer or the government via Medicare, Medicaid, and Obamacare. Likewise, health insurance companies often dictate what medical procedures or medications are allowable.
Direct primary care (DPC) changes that entire dynamic. There are some minor variations, but in its simplest form, DPC is a contract between a patient and a primary care physician. The patient usually pays a fixed amount of money per month and then has unlimited access to the medical provider for routine types of care. There is no insurance or government involvement. Most practices limit the overall number of DPC patients they will accept.
From the patient's standpoint, DPC offers real continuity of care and allows the provider to develop a meaningful relationship with the patient. From the primary care provider's perspective, there is an opportunity to really get to know their patients, there is an average savings in overhead of around 40 percent, and the provider has the ability to practice medicine without interference from any third party.
The number of DPC practices is growing, going from 100 in 2009 to over 2,500 in early 2025. A patient in a DPC practice still needs to have a major medical or catastrophic health insurance policy to cover hospitalizations or other large medical expenses. In this case, insurance functions as it should to pay for infrequent, unpredictable events rather than day-to-day medical expenses.
Half of all Americans receive their health insurance through their employer or their spouse's employer. To save costs, there is growing interest among employers to utilize DPC for their employees. Likewise, there have been DPC practices that limit themselves to the Medicaid entitlement population with initial success. Seniors in the Medicare program have the ability to access DPC as well.
Although attempts have been made by state insurance commissions to classify DPC as health insurance and to then regulate it, these attempts have been unsuccessful. By any definition, DPC is clearly not any type of insurance.
Health care costs and expenses continue to increase in the U.S. Direct primary care is an excellent tool to hold costs down, while giving patients more control over their health care decisions and dollars, and giving providers more freedom to practice medicine without third-party interference.
Dr. Roger Stark is a visiting fellow with Mountain States Policy Center, an independent research organization based in Idaho, Montana, Eastern Washington and Wyoming. Online at mountainstatespolicy.org. A retired surgeon, Dr. Stark has authored three books including 'Healthcare Policy Simplified: Understanding a Complex Issue,' and 'The Patient-Centered Solution: Our Health Care Crisis, How It Happened, and How We Can Fix It.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones - Received European and United Kingdom Medical and Healthcare Products Regulatory Agency ("MHRA") approval for EMBRACE, the Company's second pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD") on schedule - - EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia1 - - Completion of patient enrollment in CYB004 Phase 2 study in General Anxiety Disorder expected in August 20251 - - Recent financing agreement of US$50 million principal amount of convertible debentures will advance clinical pipeline programs - - Cash totaled US$118.7 million as of June 30, 2025 - This news release constitutes a "designated news release" for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025. TORONTO, August 13, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. "With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points," said Doug Drysdale, Chief Executive Officer of Cybin. "Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month." "Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective," concluded Drysdale. Recent Business and Pipeline Highlights: Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose. Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study. Clinical Program Summary CYB003: Deuterated psilocin program Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 20261. CYB003 program accomplishments: Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD. A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months: 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. CYB004: Deuterated dimethyltryptamine program The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month1. Change in Presentation Currency Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar ("USD"). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated. First-Quarter Financial Highlights Cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year. Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Note: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See "Cautionary Notes and Forward-Looking Statements". Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "potential", "possible", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. View source version on Contacts Investor & Media Contact: Gabriel FahelChief Legal OfficerCybin Inc.1-866-292-4601irteam@ – or – media@
Yahoo
an hour ago
- Yahoo
Target-owned brand of frosted sugar cookies recalled due to possible contamination with wood pieces
So far, no illnesses have been reported. Frosted sugar cookies sold at Target stores across the United States have been recalled because they may contain pieces of wood. The U.S. Food and Drug Administration issued a recall for 803 cases of Favorite Day Bakery frosted sugar cookies sold at Target stores in 20 states and Washington, D.C. Favorite Day is a private label brand sold at Target. The voluntary recall was initiated on July 22, 2025, by Give and Go Prepared Foods Corp in Etobicoke, Canada, which prepared the affected bakery items. As of Aug. 13, Target does not have the recall listed on its website. How can I identify which specific cookies are recalled? The affected Favorite Day Bakery frosted sugar cookies are the 10-count packages (Net wt. 13.5 oz.) with lot number 25195 and UPC code 85239-41250 3. 'Best By Date can vary as they are applied by retailer when removed from freezer,' the FDA indicates in the recall. Has anyone gotten sick from the cookies? No illnesses have been reported yet. However, the FDA classified the recall as Class II, which means eating the contaminated cookies 'may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' Where are the Target stores that sold the affected cookies? The FDA says the affected cookies were distributed to Target stores in the following states and D.C.: Connecticut Delaware Illinois Indiana Kentucky Maine Maryland Massachusetts Michigan Missouri New Hampshire New Jersey New York North Carolina Ohio Pennsylvania Rhode Island Tennessee Vermont Virginia Washington, D.C. I bought the cookies that were recalled. What should I do? Customers who purchased the affected frosted sugar cookies can get a full refund by bringing them to their nearest Target store or by calling Target guest relations at 1-800-440-0680. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Man took diet advice from ChatGPT, ended up hospitalized with hallucinations
A man was hospitalized for weeks and suffered from hallucinations after poisoning himself based on dietary advice from ChatGPT. A case study published on Aug. 5 in the Annals of Internal Medicine, an academic journal, states the 60-year-old man decided he wanted to eliminate salt from his diet completely. To do so, he asked ChatGPT for an alternative to salt, or sodium chloride, to which the AI chatbot suggested sodium bromide, a compound historically used in pharmaceuticals and manufacturing. While the journal noted that doctors were unable to review the original AI chat logs and that the bot likely suggested the substitution for another purpose, such as cleaning, the man purchased sodium bromide and used it in place of table salt for three months. As a result, he ended up in the ER with paranoid delusions, despite having no history of mental health problems. Convinced that his neighbor was poisoning him, the man was reluctant to even accept water from the hospital, despite reporting extreme thirst. He continued to experience increased paranoia, as well as auditory and visual hallucinations, eventually landing him an involuntary psychiatric hold after he tried to escape during treatment. What was happening to the man? Doctors determined that the man was suffering from bromide toxicity (or bromism), which can result in neurological and psychiatric symptoms, as well as others experienced by the man, including acne and cherry angiomas (bumps on the skin), fatigue, insomnia, subtle ataxia (clumsiness) and polydipsia (excessive thirst). Other symptoms of bromism can include nausea and vomiting, diarrhea, tremors or seizures, drowsiness, headache, weakness, weight loss, kidney damage, respiratory failure and coma, according to iCliniq. Bromism was once far more common due to bromide salts having been used in everyday products. In the early 20th Century, it was used in over-the-counter medications, often resulting in neuropsychiatric and dermatological symptoms, according to the study's authors. Incidents of such poisoning saw a sharp decline when the Food and Drug Administration phased out the use of bromides in pharmaceuticals between the mid 70s and late 1980s. The man was treated at the hospital for three weeks, over which time his symptoms progressively improved. USA TODAY reached out to OpenAI, the maker of ChatGPT, for comment on Wednesday, Aug. 13, but has not received a response. The company provided Fox News Digital with a statement, saying, "Our terms say that ChatGPT is not intended for use in the treatment of any health condition, and is not a substitute for professional advice. We have safety teams working on reducing risks and have trained our AI systems to encourage people to seek professional guidance." AI can 'fuel the spread of misinformation,' doctors say Doctors involved in the case study said they suspected that the patient had used ChatGPT version 3.5 or 4.0, the former of which they tested in an attempt to replicate the answers the man received. While the study's authors noted that they couldn't know exactly what the man was told without the original chat log, they did receive a suggestion for bromide as a replacement for chloride in their tests. "Though the reply stated that context matters, it did not provide a specific health warning, nor did it inquire about why we wanted to know, as we presume a medical professional would do," said study authors Dr. Audrey Eichenberger, Dr. Stephen Thielke and Dr. Adam Van Buskirk. AI carries the risk of providing information like this without context, according to the doctors. For example, it is unlikely that a medical expert would have mentioned sodium bromide at all if a patient asked for a salt substitute. "Thus, it is important to consider that ChatGPT and other AI systems can generate scientific inaccuracies, lack the ability to critically discuss results, and ultimately fuel the spread of misinformation," according to the study. This article originally appeared on USA TODAY: Man hospitalized after taking ChatGPT diet advice, study says Solve the daily Crossword